With 0.67 million shares changed hands, the volume of the stock remained lighter than its average volume of 14.86 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4191 whereas the lowest price it dropped to was $0.3602. The 52-week range on ASBP shows that it touched its highest point at $15.80 and its lowest point at $0.22 during that stretch. Beta for the stock currently stands at 0.79.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ASBP was up-trending over the past week, with a rise of 24.57%, but this was up by 25.51% over a month. Three-month performance surged to 22.69% while six-month performance fell -96.85%. The stock lost -96.53% in the past year, while it has lost -96.36% so far this year.
Float and Shares Shorts:
At present, 48.90 million ASBP shares are outstanding with a float of 39.39 million shares on hand for trading. On 2025-07-31, short shares totaled 1.1 million, which was 222.00000000000003 higher than short shares on 1751241600. In addition to Mr. Kraig T. Higginson as the firm’s Interim CEO, President & Executive Chairman of the Board, Mr. Ernest J. Scheidemann Jr. serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, ASBP reported revenue of $0.0 and operating income of -$15556480.0. The EBITDA in the recently reported quarter was -$15556480.0 and diluted EPS was -$0.42.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
